• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
  • About Us
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Considerations for the rapid deployment of vaccines against H7N9 influenza

Considerations for the rapid deployment of vaccines against H7N9 influenza

by Adam | Oct 22, 2016

Considerations for the rapid deployment of vaccines against H7N9 influenza. University of Melborne. Expert Rev Vaccines. 2014 Jul 12
Cross-conservation of T-cell epitopes: now even more relevant to (H7N9) influenza vaccine design

Cross-conservation of T-cell epitopes: now even more relevant to (H7N9) influenza vaccine design

by Adam | Oct 22, 2016

Hum Vaccin Immunother. 2014 Feb Full Text
Integrated assessment of predicted MHC binding and cross-conservation with self reveals patterns of viral camouflage

Integrated assessment of predicted MHC binding and cross-conservation with self reveals patterns of viral camouflage

by Adam | Oct 22, 2016

BMC Bioinformatics 2014, 15 (Suppl 4): S1 doi:10.1186/1471-2105-15-S4-S1.
Peptide-pulsed dendritic cells induce the hepatitis C viral epitope-specific responses of naïve human T cells

Peptide-pulsed dendritic cells induce the hepatitis C viral epitope-specific responses of naïve human T cells

by Adam | Oct 22, 2016

Vaccine. 2014 May 30;32(26):3285-92. doi: 10.1016/j.vaccine.2014.03.083. Epub 2014 Apr 8.
Human immune responses to H. pylori HLA Class II epitopes identified by immunoinformatic methods

Human immune responses to H. pylori HLA Class II epitopes identified by immunoinformatic methods

by Adam | Oct 22, 2016

PlosOne. 2014 Apr 16. Full Text
« Older Entries

Recent Posts

  • EpiVax Enters its Next Chapter with SV Health Investors
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy 
  • BEBPA Workshop: Streamlining Immunogenicity Assessment of Host Cell Proteins
  • Advancing Immunogenicity Science: EpiVax in 2025 
  • EpiVax Supports Life-Saving Programs Through Partnerships with GAIA Vaccine Foundation and Clínica Esperanza/Hope Clinic

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.